Navigation Links
Divine Corporation's Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
Date:1/22/2008

An Independent Study by the National Cancer Institute Revealed Divine No. 9 and Divine No. 8 to be Highly Effective in Inhibiting Viruses that Cause

Cervical, Vaginal and Anal Cancers in vitro

ORLANDO, Fla., Jan. 22 /PRNewswire/ -- Divine Corporation announced today an unprecedented discovery in personal lubricants that promises to revolutionize the market. The National Cancer Institute's Laboratory of Cellular Oncology has completed a laboratory study of Divine Corporation's No. 9 and No. 8 personal lubricants and determined they are highly effective in blocking infection by certain strains of human papillomaviruses (HPVs) that have been proven to cause cervical, vaginal and anal cancers [1]. Divine No. 9 and Divine No. 8 personal lubricants now offer the possibility of HPV protection while at the same time enhancing the pleasure of intimate contact.

"We began by combining natural ingredients to create the best performing intimate lubricant on the market; one that would have unique and delightful play characteristics and feel great on your skin," said Stephanie Fresonke, President of Divine Corporation. "Thanks to the breakthrough work of the National Cancer Institute research team, Divine has now been shown to be an extremely potent human papillomavirus inhibitor in their laboratory studies. While clinical tests have not yet been performed, it is tremendously exciting to offer our customers the possibility to combine pleasure and protection in a single bottle."

Divine's unique formulations include an array of natural ingredients, most notably an extract from sea kelp called carrageenan. The National Cancer Institute study, "Carrageenan is a Potent Inhibitor of Papillomavirus Infection," has shown carrageenan to be an extremely effective topical microbicide for a broad range of sexually transmitted HPVs in vitro. The experiments compared a range of consumer products containing carrageenan. Divine No. 8 and Divine No. 9 pr
'/>"/>

SOURCE Divine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
2. Personalized Medicine - The Genomic Revolution in Cardiac Care
3. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
4. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
5. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
6. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
9. Northwestern Memorial Transplant Program Initiates New Study
10. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... VIENNA , April 23, 2010 AFFiRiS ... II clinical testing.,It may therefore be possible to confirm the ... start of this efficacy study comes only five,months after the ... in several disease areas and is currently developing a total ...
... LONDON , April 23, 2010 , , ... Managing uncertainty; A Migraine For Pharma Forecasters , , , ... has its up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast ... Dealing with uncertainties is no easy task. With ...
Cached Medicine Technology:AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3
(Date:4/15/2014)... pre-diabetes in the United States have nearly doubled since 1988, ... Public Health, with obesity apparently to blame for the surge. ... has not hit all groups equally, with alarming increases in ... new research reported in the April 15, 2014 issue of ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains why ... why the virus is able to persist in the body ... an estimated 200 million people worldwide, attacks the liver cells, ... ability to fight infection. It does this by altering cells ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have published ... Oral, and Craniofacial Manifestations." The complete review by researchers ... Michael Collins, Brian L. Foster, Rachel I. Gafni, Janice ... J. Timothy Wright is published in the OnlineFirst portion ...
(Date:4/14/2014)... Orange, NJ. April 10, 2014. John DeLuca, PhD, and ... Biogen Idec to study how persons with multiple sclerosis ... Use of Actual Reality to Measure Everyday Life Functional ... this research. Dr. DeLuca is senior VP of Research ...
(Date:4/14/2014)... A new study identifies a molecule that is a ... molecule could be an important target for colorectal cancer treatment ... of microRNA-135b (miR-135b) in two animal models and human tumors ... was led by researchers at The Ohio State University Comprehensive ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Breaking bad mitochondria 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2
... an 8-year-old boy,living with epilepsy, and his mother Amy ... Inc., the exclusive sponsor of Canine,Assistants seizure response dogs. ... him to play sports, take,music lessons, and learn Tae ... seizure when his parents are not around is still ...
... Mass., April 16 Xceed Molecular, a ... analysis,systems, announced that the University of Florida ... work with primary researchers,Charles Joel Rosser, MD ... of Surgery), to perform initial verification and ...
... April 16 Consumer,Watchdog today joined L.A. City ... that health insurer Blue Cross engaged in unfair,business ... patients,after they got sick., The practice -- ... hundreds,of patients who have been left uninsured, uninsurable, ...
... Pa., April 16 Law Offices of ... potential claims against Inverness,Medical Innovations, Inc. ("Inverness ... securities law violations by Inverness Medical and,certain ... Company,s secondary,public offering on or about November ...
... Participating Courtesy of TriWest -, PHOENIX, April ... protect America,s freedoms in Iraq and Afghanistan, Marines,Chris ... injuries diminish,their spirits. Both received prosthetic limbs, returned ... courtesy of TriWest Healthcare Alliance., As members ...
... Help Build Healthy Communities, VICTORVILLE, Calif., April ... the Victorville Earth Day Eco Tote giveaway.,On Tuesday, ... offices will be handing out recyclable Eco Totes ... the Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical ...
Cached Medicine News:Health News:Young Boy With Epilepsy to Gain Independence With New Seizure Response Dog From Canine Assistants 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 3Health News:Consumer Watchdog Applauds L.A. City Attorney's Efforts to Reinstate Cancelled Blue Cross Patients; Urges State HMO Regulator to Do Same 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: